Fil: Alvarez, María G. Hospital Interzonal General de Agudos Eva Perón, Buenos Aires; Argentina.Fil: Bertocchi, Graciela Luciana. Hospital Interzonal General de Agudos Eva Perón, Buenos Aires; Argentina.Fil: Cooley, Gretchen. Center for Tropical and Emerging Global Diseases, Athens, Georgia; Estados Unidos.Fil: Albareda, María Cecilia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Viotti, Rodolfo. Hospital Interzonal General de Agudos Eva Perón, Buenos Aires; Argentina.Fil: Pérez-Mazliah, Damián E. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Lococo, Bruno. Hospital Interzonal General de Agudos Eva Perón, Buenos Aires; Argentina.Fil: Castro Eiro, Melisa D. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Laucella, Susana A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.Fil: Tarleton, Rick L. Center for Tropical and Emerging Global Diseases, Athens, Georgia; Estados Unidos.Chagas disease is the highest impact parasitic disease in Latin America. We have proposed that changes in Trypanosoma cruzi-specific immune responses might serve as surrogate indicators of treatment success. Herein, we addressed in a long-term follow-up study whether cure achieved after treatment can be predicted by changes in non-conventional indexes of anti-parasite serological and T cell activities.